Trial · NCT06697353
An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
NCT06697353, Completed, Bayer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan. Trials, record NCT06697353. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06697353
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
- NCT number
- NCT06697353
- Status
- Completed
- Enrollment
- 4,936 participants, actual
- Lead sponsor
- Bayer
- Conditions
- Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- vericiguat (BAY 1021189)
- First posted
- 2024-11-20
- Last updated
- 2025-10-08
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence rates of clinical outcomes in patients who initiate vericiguat | Retrospective analysis from September 2016 to July 2024; Up to one year after vericiguat initiation | To estimate the incidence rates of cardiovascular death, all-cause death, HF hospitalization, a composite of cardiovascular death or HF hospitalization, and a composite of all-cause death or HF hospitalization in patients who initiate vericiguat |
| Secondary | characteristics of patients who initiate vericiguat: age | Baseline | Age in years: to document the age range of patients initiating vericiguat |
| Secondary | characteristics of patients who initiate vericiguat: gender | Baseline | Gender: to document the gender distribution of patients initiating vericiguat |
| Secondary | characteristics of patients who initiate vericiguat: BMI | Baseline | BMI (in kg/m2) at baseline - To describe the weight distribution of patients who initiate vericiguat |
| Secondary | characteristics of patients who initiate vericiguat: recent Worsening Heart failure (WHF) | Baseline | Documentation of Recent WHF event: HF hospitalization within 6 months or outpatient IV diuretics within 3 months prior to index date. |
| Secondary | characteristics of patients who initiate vericiguat, prior WHF | Baseline | Prior WHF: HF hospitalization or outpatient IV diuretics with no specified evaluation period |
| Secondary | characteristics of patients who initiate vericiguat: Dialysis | Baseline | Document the number of patients on maintenance dialysis |
| Secondary | characteristics of patients who initiate vericiguat: Time from recent WHF event | Baseline | Treatment location after recent WHF event: HF hospitalization in the previous 3 months, HF hospitalization in the previous 3-6 months, and outpatient IV diuretics in the previous 3 months |
| Secondary | characteristics of patients who initiate vericiguat: Comorbidities | Baseline | Document Comorbidities at baseline |
| Secondary | characteristics of patients who initiate vericiguat: setting | Baseline | Setting of vericiguat initiation: inpatient or outpatient setting - To describe the characteristics of patients who initiate vericiguat |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06697353
GET https://conductscience.org/api/trials/v1/NCT06697353/registered?page=2